FDA Approves Updated Label For Merck's Vytorin – Update

Drug maker Merck & Co. Inc. (MRK) said Wednesday that the U.S. Food and Drug Administration has approved an updated label for its cardiovascular drug Vytorin that includes results from a study, which shows that the drug effectively lowered bad cholesterol in patients with moderate to severe kidney disease and also reduced major vascular events.

Leave a Reply

Your email address will not be published.